Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Q1 2025 · 10-Q
Revenue$4.66B$4.66B+20.9% vs Q1 2024 Net Income$672.00M$672.00M+36.3% vs Q1 2024 EPS Diluted$0.45$0.45+36.4% vs Q1 2024 Gross Profit$3,210,000,000+21.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
Operating Cash Flow$541,000,000+229.9% Free Cash Flowderived$354,000,000N/M Margins · derivedGross margin68.8%+0.2 pt vs Q1 2024
Operating margin19.8%+2.2 pt vs Q1 2024
Net margin14.4%+1.6 pt vs Q1 2024
ended Mar 31, 2025 · filed May 1, 2025 · 31 d after period end